Navigation Links
International Survey of T2* Cardiovascular Magnetic Resonance in Thalassemia
Date:6/15/2012

AMSTERDAM, June 15, 2012 /PRNewswire/ --

"There is a large potential opportunity for saving lives by early identification of cardiac iron loading in Thalassemia patients", declares Professor John-Paul Carpenter of the Royal Brompton CMR Unit in London at the 17th Congress of the European Hematology Association in Amsterdam.

Thalassemia major (TM) is a substantial health issue, with over 25,000 new transfusion-dependent children identified each year around the world. In most TM patients who receive regular transfusions, the accumulation of cardiac iron is the cause of heart failure and early death. T2* cardiovascular magnetic resonance (CMR) provides a calibrated and reproducible measurement of myocardial iron which has contributed to improved survival in TM patients. However, there is little data regarding myocardial iron loading and its relation to outcome across the world.

We report a survey of 3,411 patients in 34 centres which use T2* CMR. Even in this cohort of well-treated TM patients from across the world which had access to regular transfusion, chelation and T2* CMR, a large proportion (42.3%) had moderate or severe myocardial iron loading. There were substantial regional differences in the prevalence of cardiac iron overload which, despite differences in clinical care, may indicate varying predisposition to myocardial iron loading. T2* CMR identified those patients at increased risk with myocardial T2* values <10ms being strongly associated with the future development of cardiac failure and death. There is a large potential opportunity for saving lives by early identification of cardiac iron loading and T2* CMR needs to be more widely available.

About the EHA Annual Congress

After 16 congresses and constantly increasing number of delegates, the 17th Congress of EHA is taking place in Amsterdam. Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases (in the production) of blood and their treatments. The latest data on research and developments within the wide spectrum of hematology are presented.


'/>"/>
SOURCE European Hematology Association
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. PAREXEL International To Present At Goldman Sachs Healthcare Conference And Jefferies Healthcare Conference
2. QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio
3. Goddard collaborates with international partners on MMS instrument
4. Dyadic International To Release First Quarter 2012 Financial Results And Host Conference Call
5. GDS International Combines Top Healthcare Executives in the United States for its 10th Anniversary NG Healthcare Summit in May
6. Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference
7. Dyadic International Partners with Leading Provider of Nutritional Ingredient Solutions for Production of Food Enzymes
8. Bacterin International Holdings, Inc. Schedules Fourth Quarter 2011 Financial Earnings Conference Call
9. Alchem International Opens Sales and Marketing Office in the U.S.
10. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
11. First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... JOSE, Calif. , Feb. 23, 2017 /PRNewswire/ ... exclusive license for two key immunotherapy technologies from ... first technology provides a method to monitor a ... such as PD-L1 and CTLA-4.  The second license ... if a patient is likely to have an ...
(Date:2/23/2017)... San Antonio, TX (PRWEB) , ... February 23, ... ... and Drug Administration (FDA) de novo clearance to begin marketing the SPEAC® System, ... is indicated for adults at home or in healthcare facilities during periods of ...
(Date:2/23/2017)... ... ... The Greater Gift Initiative, Inc , (GGI) a Winston-Salem, NC 501(c)3 non-profit, ... is to advance global health and highlight the greater good of clinical trial participation ... trial volunteer. The vision of GGI is to serve as a philanthropic connector between ...
(Date:2/23/2017)... ... February 22, 2017 , ... Seventy-one ... been named Fellows of the Society this year, the Fellows Committee has announced. ... fields of optics, photonics, and imaging as well as their service to the ...
Breaking Biology Technology:
(Date:2/7/2017)... , February 7, 2017 ... Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") ... electronic transaction processing services, is pleased to announce the ... Company. Effective January 31, 2017, Philip ... of Directors, CEO and President.  An experienced payment industry ...
(Date:2/3/2017)...  Texas Biomedical Research Institute announced that its Board of ... as the Institute,s new President and CEO. Dr. Schlesinger will ... He is currently the Chair of the Department of Microbial ... Interface Biology at Ohio State University. "We are ... CEO of Texas Biomed," said Dr. James O. Rubin ...
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
Breaking Biology News(10 mins):